ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R(2)-CHOP) improved outcomes relative t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Future Oncol
Päätekijät: Nowakowski, Grzegorz S, Chiappella, Annalisa, Witzig, Thomas E, Spina, Michele, Gascoyne, Randy D, Zhang, Lei, Flament, Jocelyne, Repici, Jacqueline, Vitolo, Umberto
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Future Medicine Ltd 2016
Aiheet:
Clinical Trial Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5551933/
https://ncbi.nlm.nih.gov/pubmed/27089170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0130
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia